Search clinical trials for: Afatinib

Total 233 results

Boehringer Ingelheim

Completed

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Stomach Neoplasms | Breast Neoplasms

France
Boehringer Ingelheim

Terminated

LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy

Head and Neck Neoplasms

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Czechia, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Mexico, Netherlands, Portugal, Russian Federation, Spain, Sweden, Switzerlan... and more
Groupe Oncologie Radiotherapie Tete et Cou

Completed

Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy (TAPIS)

HNSCC

France
Memorial Sloan Kettering Cancer Center
Boehringer Ingelheim; National Comprehensive Cancer Network

Completed

Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC)

Head and Neck Cancer | Squamous Cell Cancer

United States
Boehringer Ingelheim

Terminated

Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)

Carcinoma, Non-Small-Cell Lung | ErbB Receptors

United States
Groupe Hospitalier Paris Saint Joseph

Withdrawn

Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex (THEN)

SMALL CELL LUNG CARCINOMA

France
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant Glioma

Glioma

United States, Canada
PD Dr. med. Volker Heinemann
Boehringer Ingelheim

Unknown

Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours (ACCEPT)

Focus of Study Instead

Germany
Boehringer Ingelheim

Completed

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Neoplasms

France, Spain
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Acetylcysteine, Mannitol, Combination Chemotherapy, and Sodium Thiosulfate in Treating Children With Malignant Brain Tumors

Brain and Central Nervous System Tumors | Long-term Effects Secondary to Cancer Therapy in Children | Drug/Agent Toxicity by Tissue/Organ | Bone Marrow Suppression

United States
Boehringer Ingelheim

Completed

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Austria, Germany, Spain, China, Taiwan, Argentina, Australia, Belgium, Brazil, Finland, France, Hungary, India, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Peru, Poland, Russian Federation, Ukraine, United Kingdom
Boehringer Ingelheim

Completed

Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations

Carcinoma, Non-Small-Cell Lung

Canada
Assistance Publique - Hôpitaux de Paris
Institut National de la Santé Et de la Recherche Médicale, France

Completed

Validation of the Percentage of Alveolar Fibrocyte as Biomarker During ARDS (IFRA2)

Mechanical Ventilation | Acute Respiratory Distress Syndrome (ARDS)

France
Columbia University
Boehringer Ingelheim

Withdrawn

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Esophageal Cancer | Gastrooesophageal Cancer | HER-2 Positive Gastric Cancer
Instituto Nacional de Cancerologia de Mexico

Unknown

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

EGFR Gene Mutation | Tyrosine Kinase Mutation | Non-Small Cell Adenocarcinoma

Mexico
Boehringer Ingelheim

Completed

A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations

Carcinoma, Non-Small-Cell Lung

United States
Boehringer Ingelheim

Approved for marketing

Afatinib Expanded Access Program

Carcinoma, Non-Small-Cell Lung

United States
Boehringer Ingelheim

Approved for marketing

LUX Lung Special Access Scheme Australia Named Patient Use (NPU)

Carcinoma, Non-Small-Cell Lung

Australia
Virginia Simnad
Biogen

Unknown

Impact of Tecfidera on Gut Microbiota

Multiple Sclerosis

United States
Boehringer Ingelheim

Completed

ADAM-Afatinib Diarrhea Assessment and Management

Carcinoma, Non-Small-Cell Lung

United States
SciClone Pharmaceuticals

Unknown

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

EGFR Mutation Positive Non Small Cell Lung Cancer

Italy
Boehringer Ingelheim

Completed

LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating Mutations

Carcinoma, Non-Small-Cell Lung

United States, Taiwan
Boehringer Ingelheim

Completed

BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)

Carcinoma, Non-Small-Cell Lung

United States, Belgium, Canada, China, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, Singapore, Spain, Taiwan, Thailand, United Kingdom
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) in Head & Neck Cancer

Head and Neck Neoplasms | Carcinoma, Squamous Cell

United States, Belgium, France, Spain
Biogen

Completed

Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS (RESPOND)

Relapsing Forms of Multiple Sclerosis

United States
Boehringer Ingelheim

Completed

Afatinib (BIBW2992) in HER2 (Human Epidermal Growth Factor Receptor 2)-Overexpressing Inflammatory Breast Cancer

Breast Neoplasms

United States, Australia, Hong Kong, Korea, Republic of, Thailand, Tunisia, United Kingdom
Boehringer Ingelheim

Completed

A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

Neoplasms

France
National Taiwan University Hospital

Unknown

Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of Afatinib

Triple Negative Breast Cancer

Taiwan
Boehringer Ingelheim

Completed

Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid Tumours

Neoplasms

United Kingdom
European Organisation for Research and Treatment...

Suspended

Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer. (REMNANT)

Non Small Cell Lung Cancer
Boehringer Ingelheim

Completed

Afatinib in Subjects With Kidney Dysfunction

Renal Insufficiency

Germany
The University of Hong Kong

Completed

Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC

Lung Cancer

Hong Kong
Boehringer Ingelheim

Completed

Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Spain
Boehringer Ingelheim

Completed

Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Netherlands
Boehringer Ingelheim

Completed

Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain Metastases

Breast Neoplasms | Neoplasm Metastasis

United States, Canada, Finland, France, Germany, Italy, Korea, Republic of, Spain
Nordic Life Science Pipeline Inc.
United States Department of Defense

Completed

Study to Assess Safety, Tolerability and MTD of a Central Pattern Generator-activating Tritherapy (SPINALON) in Patients With Chronic Spinal Cord Injury

Spinal Cord Injury

Canada
Boehringer Ingelheim

Completed

Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.

Neoplasms

France
Boehringer Ingelheim

Completed

Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.

Breast Neoplasms

United Kingdom
The University of Texas Health Science Center,...

Completed

Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea

Diarrhea

Mexico
Boehringer Ingelheim

Completed

Dose Escalation Study of BIBW 2992 in Patients With Advanced Solid Tumors

Neoplasms
Boehringer Ingelheim

Completed

LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Carcinoma, Non-Small-Cell Lung

Japan
Boehringer Ingelheim

Completed

A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate Cancer

Prostatic Neoplasms

United Kingdom
Biogen

Completed

A Healthy Volunteer Study to Establish the Bioequivalence of BG00012 Supplied by 2 Different Commercial Manufacturers

Healthy

United States
Boehringer Ingelheim

Terminated

Pharmacokinetic Study of Porfiromycin in Head and Neck Cancer and Other Cancer Patients With Solid Tumors

Head and Neck Neoplasms
Boehringer Ingelheim

Completed

BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients

Carcinoma, Non-Small-Cell Lung

Italy
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid Tumours

Neoplasms

Japan
Boehringer Ingelheim

Completed

A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United Kingdom
Boehringer Ingelheim

Completed

BIBW 2992 in Patients With Advanced Solid Tumors

Neoplasms
Boehringer Ingelheim

Completed

BIBW 2992 Administered as Tablet (Final Formulation) Compared to BIBW 2992 Drinking Solution and BIBW 2992 Tablet (Trial Formulation II) in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety and Tolerability of 4 Different Dosage Strengths of BIBW 2992 Tablets to Healthy Male Volunteers

Healthy

3

Subscribe